Skip to main content

Day: February 10, 2025

Alaris Equity Partners Announces Timing of 2024 Q4 Financial Results, Conference Call and Webcast

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW. CALGARY, Alberta, Feb. 10, 2025 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce that it will release its year-end results for the period ended December 31, 2024 following the closing of regular trading on the Toronto Stock Exchange Monday, March 10, 2025. Alaris management will host a conference call at 9 am MT (11am ET) the following day, Tuesday, March 11, 2025 to discuss the financial results and outlook for the Trust. Participants must register for the call using this link: Pre-registration to Q4 to receive the dial-in numbers and unique PIN to access the call seamlessly. It is recommended...

Continue reading

Regulated information – Disclosure of share buy-back transactions completed from 03 February 2025 to 09 February 2025

In compliance with share buyback regulations, in particular Regulation (EU) 2016/1052, SPIE discloses the following transactions completed from 03 February 2025 to 09 February 2025 under the share buyback programme authorised by the 10th resolution of the SPIE general shareholders’ meeting held on 3 May 2024 and announced on 9 January 2025: Aggregate disclosure per day and per marketName of the issuer Identity code of the Issuer (LEI) Day of transaction ISIN Code Total daily volume (in number of shares) Daily weighted average price of the purchased shares (in euros) Market (MIC Code)SPIE 969500TJNS5GSFWJ8X85 03/02/2025 FR0012757854 53 000 31.6632 XPARSPIE 969500TJNS5GSFWJ8X85 03/02/2025 FR0012757854 22 076 31.6803 CEUX  Total daily volume (in number of shares) Daily weighted average price of the purchased shares (in...

Continue reading

Wyse Meter Solutions acquires full ownership of EVSTART and Rate Switch

CONCORD, Ontario, Feb. 10, 2025 (GLOBE NEWSWIRE) — Wyse Meter Solutions is pleased to announce the successful acquisition of full ownership of EVSTART and the Rate Switch program, marking a significant milestone in the company’s ongoing mission to deliver innovative, client-focused solutions in the multi-residential sector. EVSTART, a cutting-edge electric vehicle (EV) charging solution, was originally developed in partnership with Elexicon Group to address the unique infrastructure challenges of multi-residential buildings. By delivering tailored solutions, advanced technology, and comprehensive support, EVSTART simplifies EV adoption for building owners, property managers, and residents, making the transition to sustainable transportation seamless. The Rate Switch program, previously a proprietary offering of Elexicon Group,...

Continue reading

Issue of Equity – Correction

Foresight VCT PLCLEI: 213800GNTY699WHACF46 CORRECTION: Issue of EquityAllotment of Ordinary Shares10 February 2025 Foresight VCT Plc (the “Company”) wishes to notify the correction of errors to the allotment figure and total number of shares in the announcement dated 10 February 2025 concerning the allotment of shares on 7 February 2025 under the offer for subscription contained in the prospectus issued by the Company dated 10 December 2024. The corrected details are as follows: The Board of Foresight VCT plc (“the Company”) is pleased to announce that 15,140,285 Ordinary Shares of 1p each in the capital of the Company (“the Shares”) were allotted on 7 February 2025 pursuant to the offer for subscription (“the Offer”) contained in the prospectus issued by the Company dated 10 December 2024. The Shares were issued at offer prices based...

Continue reading

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

FDA RMAT designation follows positive proof-of-concept U.S. clinical data from the NXC-201 NEXICART-2 clinical trial in relapsed/refractory AL Amyloidosis RMAT designation potentially streamlines the path to market approval by allowing frequent interactions with FDA and routes to FDA Accelerated Approval and Priority Review Enrollment in NEXICART-2 study accelerating; next update planned for H1 2025LOS ANGELES,CA, Feb. 10, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and select immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of relapsed/refractory AL...

Continue reading

Yes& Deepens B2B Capabilities with the Acquisition of Beacon Digital Marketing

Clients Gain Access to Enhanced Digital Strategy and Execution as Beacon Joins Yes& Washington, DC, Feb. 10, 2025 (GLOBE NEWSWIRE) — Yes&—a premiere, full-service marketing and advertising agency based in greater Washington, DC, with hubs in Philadelphia and Chicago—announced today the acquisition of Beacon Digital Marketing, a leading digital marketing agency based in New York. This move strengthens Yes&’s ability to deliver world-class digital strategy, performance marketing, creative branding, and marketing automation to its growing client base. Yes&’s leadership was attracted to Beacon for its strong B2B track record in industries such as fintech, cybersecurity, professional services, and SaaS, and its deep expertise delivering measurable results through integrated digital campaigns, website design and development,...

Continue reading

Annual Volcon CEO Update

AUSTIN, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) — After one year of John Kim at the helm of Volcon ePowersports, their recent successes can be attributed to his strategic shift. In the last 12 months Mr. Kim was able to switch Volcon from being a mostly R&D organization developing its own electric offroad technologies into a company that is focused on collaborating with manufacturers to brand and sell high-quality electric vehicles. This has positioned Volcon to be a true disruptor in the ePowersports business, which was made especially apparent with their recent AODES (Super Sonic) collaboration. Volcon’s AODES (Super Sonic) announcement allowed them to raise $19.45 million to fund their foray into the golf cart and utility vehicle market. Bringing high-quality, low-cost electric vehicles from Vietnam into the US market creates...

Continue reading

Varonis Announces $100 Million Share Repurchase Authorization

MIAMI, Feb. 10, 2025 (GLOBE NEWSWIRE) — Varonis Systems, Inc. (Nasdaq: VRNS), a leader in data security, announced that its board of directors authorized a share repurchase program allowing repurchases of up to $100.0 million of Varonis’ common stock expected to be completed over the next 12 months. Under the share repurchase program, Varonis is authorized to repurchase shares through open market purchases, privately-negotiated transactions or otherwise in accordance with applicable federal securities laws, including through Rule 10b5-1 trading plans and under Rule 10b-18 of the Exchange Act. The number of shares to be purchased and the timing of purchases will be based on Varonis’ trading windows, available liquidity, and general business and market conditions. Forward-Looking Statements This press release contains “forward-looking”...

Continue reading

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Data Safety Monitoring Committee (DSMC) has recently completed its second independent review of the ongoing ORCA-OL trial, evaluating long-term exposure of the novel 3 mg cytisinicline treatment dosing regimen in individuals who smoke cigarettes or vape nicotine. Following this second comprehensive review of available safety data, the DSMC stated that it did not identify any unexpected...

Continue reading

GEN Korean BBQ Expands Footprint in Texas with New Location in San Antonio

This Marks the Third Location Opening in 2025 Signaling Strong Growth Momentum for the Year CERRITOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) — GEN Restaurant Group, Inc. (“GEN” or the “Company”) (Nasdaq: GENK), owner of GEN Korean BBQ, a fast-growing casual dining concept with an extensive menu and signature “grill at your table” experience, today announced a new restaurant location in San Antonio, Texas, which opened on January 31, 2025. This marks the Company’s third new opening in January, following successful additions in Edison, New Jersey and Orlando, Florida. “Opening a sixth Texas location in a new market was a natural choice for GEN given the strong performance of our existing Texas locations and desire to continue building momentum across the state,” said David Kim, Chairman and CEO of GEN. “We are proud to have started...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.